Loading clinical trials...
Loading clinical trials...
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) and Subjects With Diabetic Macular Edema (DME)
Conditions
Interventions
AR-13503 Implant 10.6 Dose
AR-13503 Implant 21.2 Dose
+2 more
Locations
6
United States
Retinal Research Institute, LLC
Gilbert, Arizona, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Sterling Vision, PC dba Oregon Retina
Eugene, Oregon, United States
Valley Retina Institute, P.A.
Harlingen, Texas, United States
Medical Center Ophthamology Associates
San Antonio, Texas, United States
Start Date
June 24, 2019
Primary Completion Date
May 12, 2022
Completion Date
May 12, 2022
Last Updated
February 9, 2023
NCT07425522
NCT07308639
NCT07449936
NCT07449923
NCT06439576
NCT07228559
Lead Sponsor
Aerie Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions